Synaptic Pharmaceutical Corp. signed a definitive merger agreement with like-minded central nervous system-focused H. Lundbeck A/S in a deal worth about $121 million. (BioWorld Today)

Synaptic Pharmaceutical Corp. signed a definitive merger agreement with like-minded central nervous system-focused H. Lundbeck A/S in a deal worth about $121 million. (BioWorld Today)

Avanir Pharmaceuticals Inc. reported positive results from one of two planned pivotal trials testing Neurodex in pseudobulbar affect, a somewhat rare tragedy/comedy neurological affliction that affects up to an estimated 1 million people in the U.S. each year. (BioWorld Today)

Avanir Pharmaceuticals Inc. reported positive results from one of two planned pivotal trials testing Neurodex in pseudobulbar affect, a somewhat rare tragedy/comedy neurological affliction that affects up to an estimated 1 million people in the U.S. each year. (BioWorld Today)